Our study revealed that elevation of stress‐inducible protein SESN2 expression participated in activating AKT signaling as a novel positive upstream regulator, which replenishes and expands the molecular network of sorafenib primary resistance in HCC and provides a potential target to increase sorafenib treatment efficacy. This evidence concerns the gene SESN2 and hepatocellular carcinoma.